Haha go slow with enrollments? Have enrollments been fast over the past few years?
It's clear they needed to redesign the trial. I remember previously working out they were on track to complete phase 1b enrollment in 2028 if the enrollment rate stayed the same as it had been. It was just taking far too long.
At least CDH17 has broader patient population and ease of administration (compared to CLTX, it is still an autologous CAR-T therapy after all). So hopefully well see a bit more data from that trial over the next year or two.
Ann: Investor Presentation, page-34
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.6¢ | $27.84K | 1.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1060707 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 239000 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| CHM (ASX) Chart |